RitaAssiMD

Hematologic Oncology

Assistant Professor of Medicine

Dr. Assi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

A nontandem novel compound chimeric antigen receptor redirected to target CD20-CD19 positive B-cell acute leukemias and B-cell lymphoma.
Vincent M DeStefano, Masayuki Wada, Kevin G Pinz, Rita Assi, Hongyu Zhang
Clinical and Translational Medicine. 2024-07-01
51 citations
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
Daniel A Pollyea, Jessica K Altman, Rita Assi, Dale Bixby, Amir T Fathi
Journal of the National Comprehensive Cancer Network. 2023-05-01
7 citations
Sarcopenia Predicts Inferior Progression-Free Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation.
Nuttavut Sumransub, Qing Cao, Mark Juckett, Brian Betts, Shernan Holtan
Transplantation and Cellular Therapy. 2023-04-01

Abstracts/Posters

Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Periphera...
Rita Assi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Diverse Landscape of TET2 Variants in MDS and AML
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018